Altrinsic Global Advisors LLC Bristol Myers Squibb CO Transaction History

Altrinsic Global Advisors LLC

  • $2.15 Billion
  • Q3 2024

A detailed history of Altrinsic Global Advisors LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Altrinsic Global Advisors LLC holds 277,270 shares of BMY stock, worth $15.9 Million. This represents 0.67% of its overall portfolio holdings.

Number of Shares
277,270
Previous 284,988 2.71%
Holding current value
$15.9 Million
Previous $11.8 Million 21.23%
% of portfolio
0.67%
Previous 0.57%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$39.66 - $51.75 $306,095 - $399,406
-7,718 Reduced 2.71%
277,270 $14.3 Million
Q2 2024

Aug 14, 2024
SELL
$40.25 - $52.99 $469,274 - $617,810
-11,659 Reduced 3.93%
284,988 $11.8 Million
Q1 2024

May 14, 2024
SELL
$47.98 - $54.4 $933,546 - $1.06 Million
-19,457 Reduced 6.16%
296,647 $16.1 Million
Q4 2023

Feb 14, 2024
SELL
$48.48 - $57.85 $6.1 Million - $7.28 Million
-125,893 Reduced 28.48%
316,104 $16.2 Million
Q3 2023

Nov 14, 2023
SELL
$57.89 - $64.73 $1.2 Million - $1.34 Million
-20,731 Reduced 4.48%
441,997 $25.7 Million
Q2 2023

Aug 14, 2023
BUY
$63.71 - $70.74 $2.57 Million - $2.85 Million
40,278 Added 9.53%
462,728 $29.6 Million
Q1 2023

May 15, 2023
BUY
$65.71 - $74.53 $70,441 - $79,896
1,072 Added 0.25%
422,450 $29.3 Million
Q4 2022

Feb 14, 2023
SELL
$68.48 - $81.09 $1.9 Million - $2.24 Million
-27,673 Reduced 6.16%
421,378 $30.3 Million
Q3 2022

Nov 14, 2022
SELL
$0.13 - $76.84 $8,273 - $4.89 Million
-63,640 Reduced 12.41%
449,051 $31.9 Million
Q2 2022

Aug 15, 2022
SELL
$72.62 - $79.98 $3.92 Million - $4.32 Million
-54,004 Reduced 9.53%
512,691 $39.5 Million
Q1 2022

May 16, 2022
SELL
$61.48 - $73.72 $13.3 Million - $15.9 Million
-216,092 Reduced 27.61%
566,695 $41.4 Million
Q4 2021

Feb 14, 2022
BUY
$53.63 - $62.52 $2.41 Million - $2.81 Million
45,002 Added 6.1%
782,787 $48.8 Million
Q3 2021

Nov 15, 2021
SELL
$59.17 - $69.31 $1.44 Million - $1.69 Million
-24,409 Reduced 3.2%
737,785 $43.7 Million
Q2 2021

Aug 13, 2021
SELL
$61.91 - $67.42 $744,963 - $811,264
-12,033 Reduced 1.55%
762,194 $50.9 Million
Q1 2021

May 14, 2021
SELL
$59.34 - $66.74 $823,105 - $925,750
-13,871 Reduced 1.76%
774,227 $48.9 Million
Q4 2020

Feb 16, 2021
BUY
$57.74 - $65.43 $4.93 Million - $5.59 Million
85,428 Added 12.16%
788,098 $48.9 Million
Q3 2020

Nov 16, 2020
BUY
$57.43 - $63.64 $506,934 - $561,750
8,827 Added 1.27%
702,670 $42.4 Million
Q2 2020

Aug 14, 2020
SELL
$54.82 - $64.09 $927,992 - $1.08 Million
-16,928 Reduced 2.38%
693,843 $40.8 Million
Q1 2020

May 14, 2020
SELL
$46.4 - $67.43 $4.48 Million - $6.52 Million
-96,646 Reduced 11.97%
710,771 $39.6 Million
Q4 2019

Feb 14, 2020
SELL
$49.21 - $64.19 $11.2 Million - $14.6 Million
-227,333 Reduced 21.97%
807,417 $51.8 Million
Q3 2019

Nov 14, 2019
BUY
$42.77 - $50.71 $5.11 Million - $6.05 Million
119,396 Added 13.04%
1,034,750 $52.5 Million
Q2 2019

Aug 14, 2019
BUY
$44.62 - $49.34 $1.18 Million - $1.3 Million
26,373 Added 2.97%
915,354 $41.5 Million
Q1 2019

May 14, 2019
BUY
$45.12 - $53.8 $15.7 Million - $18.7 Million
347,173 Added 64.08%
888,981 $42.4 Million
Q4 2018

Feb 14, 2019
BUY
$48.76 - $63.23 $25.6 Million - $33.2 Million
524,858 Added 3096.51%
541,808 $28.2 Million
Q2 2018

Aug 13, 2018
BUY
$50.53 - $62.98 $480,237 - $598,561
9,504 Added 127.64%
16,950 $938,000
Q4 2017

Feb 13, 2018
BUY
$59.94 - $65.35 $26,553 - $28,950
443 Added 6.33%
7,446 $456,000
Q3 2017

Nov 14, 2017
BUY
$55.23 - $63.74 $386,775 - $446,371
7,003
7,003 $446,000

Others Institutions Holding BMY

# of Institutions
2,536
Shares Held
1.47B
Call Options Held
31.6M
Put Options Held
35M
View Full List

About BRISTOL MYERS SQUIBB CO

BMY Quotes by TradingView
  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Altrinsic Global Advisors LLC Portfolio

Follow Altrinsic Global Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altrinsic Global Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Altrinsic Global Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email